The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
NLRP3 inflammasome and its inhibitors: a review
|
|---|---|
| Published in |
Frontiers in Pharmacology, November 2015
|
| DOI | 10.3389/fphar.2015.00262 |
| Pubmed ID | |
| Authors |
Bo-Zong Shao, Zhe-Qi Xu, Bin-Ze Han, Ding-Feng Su, Chong Liu |
| Abstract |
Inflammasomes are newly recognized, vital players in innate immunity. The best characterized is the NLRP3 inflammasome, so-called because the NLRP3 protein in the complex belongs to the family of nucleotide-binding and oligomerization domain-like receptors (NLRs) and is also known as "pyrin domain-containing protein 3". The NLRP3 inflammasome is associated with onset and progression of various diseases, including metabolic disorders, multiple sclerosis, inflammatory bowel disease, cryopyrin-associated periodic fever syndrome, as well as other auto-immune and auto-inflammatory diseases. Several NLRP3 inflammasome inhibitors have been described, some of which show promise in the clinic. The present review will describe the structure and mechanisms of activation of the NLRP3 inflammasome, its association with various auto-immune and auto-inflammatory diseases, and the state of research into NLRP3 inflammasome inhibitors. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 20% |
| Unknown | 4 | 80% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 745 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Brazil | 2 | <1% |
| Germany | 1 | <1% |
| China | 1 | <1% |
| Unknown | 739 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 110 | 15% |
| Student > Ph. D. Student | 107 | 14% |
| Researcher | 89 | 12% |
| Student > Bachelor | 88 | 12% |
| Student > Doctoral Student | 41 | 6% |
| Other | 105 | 14% |
| Unknown | 205 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 116 | 16% |
| Agricultural and Biological Sciences | 112 | 15% |
| Medicine and Dentistry | 110 | 15% |
| Immunology and Microbiology | 62 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 40 | 5% |
| Other | 84 | 11% |
| Unknown | 221 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 July 2023.
All research outputs
#1,380,616
of 26,397,269 outputs
Outputs from Frontiers in Pharmacology
#541
of 20,391 outputs
Outputs of similar age
#19,727
of 297,841 outputs
Outputs of similar age from Frontiers in Pharmacology
#5
of 93 outputs
Altmetric has tracked 26,397,269 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20,391 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 297,841 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 93 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.